BACKGROUND: Wild-type transthyretin cardiac amyloidosis (ATTRwt CA) is increasingly recognized as an important cause of heart failure and arrhythmias in older people. There are several clinical, echocardiographic, electrocardiographic (ECG) and laboratory features that increase the suspicion for ATTRwt CA. Presentation and phenotype can, however, be associated with atypical findings making it difficult to make a correct diagnosis. A 65-year-old man was admitted for an acute coronary syndrome. Echocardiography revealed diffuse concentric left ventricular (LV) thickening. Because of a history of bilateral carpal tunnel syndrome and polyneuropathy, the patient underwent dedicated laboratory testing and diphosphonate scintigraphy the results of which were suggestive of transthyretin cardiac amyloidosis. Also, a dynamic LV outflow tract obstruction due to the systolic anterior motion of the anterior mitral valve was noted on echocardiography during the initial investigations. Genetic testing for hypertrophic cardiomyopathy was negative. Seeking a conclusive diagnosis, endomyocardial biopsy was performed. This confirmed the diagnosis of ATTRwt CA. DISCUSSION: The presence of dynamic LV outflow tract obstruction is typically seen in patients with sarcomeric hypertrophic cardiomyopathy. It can be rarely seen also in individuals with cardiac amyloidosis, including ATTR-wt CA. The presence of so-called red flags in patients' history, physical examination, laboratory test, ECG and imaging should raise suspicion for other etiologies of LV wall thickening than hypertrophic cardiomyopathy. Although noninvasive diagnosis of ATTRwt CA is possible in most patients, endomyocardial biopsy remains necessary in cases with diagnostic ambiguity.

2nd Department of Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University Prague and General University Hospital Prague U Nemocnice 2 128 08 Prague 2 Czech Republic

Department of Internal Medicine Hospital Strakonice Strakonice Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23:512–26. PubMed DOI

Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–60. PubMed DOI

Dinwoodey DL, Skinner M, Maron MS, Davidoff R, Ruberg FL. Light-chain amyloidosis with echocardiographic features of hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:674–6. PubMed DOI

Huntrakul A, Phowthongkum P, Sitticharoenchai P, Chantadisai M, Puwanant S, Boonyaratavej S, et al. Transthyretin Amyloidosis Mimicking Obstructive Hypertrophic Cardiomyopathy: A Great Imitator. Heart Lung Circ. 2019;28:e108–e10. PubMed DOI

Mookadam F, Haley JH, Olson LJ, Cikes M, Mookadam M. Dynamic left ventricular outflow tract obstruction in senile cardiac amyloidosis. Eur J Echocardiogr. 2006;7:465–8. PubMed DOI

González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–94. PubMed DOI

Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398–408. PubMed DOI

Longinow J, Helou MCE, Finet JE, Moudgil R, Jaber W, et al. Left Ventricular Outflow Tract Obstruction In Cardiac Amyloidosis. J Cardiac Fail. 2024;30:233–4. DOI

Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996–2000). Cardiovasc Pathol. 2003;12:149–58. PubMed DOI

Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc‑3,3‑diphosphono‑1,2‑propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–84. PubMed DOI

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133:2404–12. PubMed DOI